Lutetium-177-DGUL

· Cellbion Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lutetium-177-DGUL, covering 2025-11-24 to 2025-11-24. Get the full timeline:

Most recent: Clinical Trial Update: Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer [Phase 1]